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Prostate cancer is the most commonly diagnosed 
malignancy in male. Although early prostate cancer 
is eminently treatable due to hormone dependency, 
androgen withdrawal results in incurability of its ad-
vanced stage because of the inevitable emergence 
of androgen-independent cells within few years [1]. 
Thus hormone-refractory prostate cancer has long 
been recognized as a chemo-resistance disease, 
and there is a great need novel therapeutic strategies 
that target the molecular basis of hormone refractory 
chemo-resistance of prostate cancer. Recently, it was 
reported that clusterin and inhibitors of apoptosis 
proteins (IAPs) are related to chemo-resistance in 
some cancer cells including prostate cancer [2–6]. 
Furthermore, the targeted downregulation of XIAP or 
survivin genes have been shown to directly sensitize 
cancer cells to apoptosis induced by various conven-
tional chemotherapeutic drugs [7, 8]. Clusterin (also 
known as ApoJ, TRPM-2, and SGP-2) is a secretory 
glycoprotein known as an anti-apoptotic protein [9–
14]. Survivin and XIAP belong to a family of IAPs that 
have been shown to prevent chemotherapy-induced 
apoptosis by inhibiting caspase [15, 16].
Camptothecin (CPT) specifically targets topoisome-
rase I (Top1), which is required for maintenance of 
double helical structure of DNA [17]. Studies by Wang et 
al. and our data [18, 19] demonstrated that CPT induces 
growth inhibition and apoptosis in a time- and dose-de-
pendent manner in androgen-sensitive prostate cancer 
cells (LNCaP), but not in androgen–resistant PC-3 cells. 
However, the precise mechanism underling the different 
sensitivity to CPT between these cell types remains to 
be explored. As an approach to gain some insight into 
the CPT-resistance, we have examined the expression 
levels of clusterin, survivin and XIAP and the changes in 
during CPT treatment in LNCaP and PC-3 cells.
Materials and Methods
Cell culture. LNCaP and PC-3 human prostate can-
cer cells were cultured in RPMI 1640 (Nikken Bio Medical 
Laboratory, Kyoto, Japan) supplemented with 10% fetal 
bovine serum (Sigma, USA) under a humidified atmo-
sphere of 5% CO2 and 95% air at 37 °C. (S)-(+)-camp-
tothecin (CPT) (Sigma, USA) dissolved in DMSO was 
added to the cell cultures with final DMSO concentration 
less than 0.03% v/v, which had no significant effect on 
the growth and differentiation of LNCaP and PC-3 cells. 
0.03% DMSO treatment was used as control.
Cell death assay. To identify apoptotic or necrotic cell 
death, double staining with Hoechst 33342 and propidium 
iodide (PI) was performed. Cells were stained with 5 µg/ml 
Hoechst 33342 (Calbiochem, San Diego, CA, USA) and 
2 µg/ml PI (Invitrogen, Carlsbad, CA, USA) for 20 min. After 
washing with phosphate-buffered saline (PBS), cells were 
observed under a fluorescence microscope, Olympus 
BX-51 (Olympus, Tokyo, Japan). To evaluate the type of 
cell death, over 500 cells were analyzed.
Western blotting. Antibodies used were rabbit 
polyclonal anti-survivin (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), rabbit polyclonal anti-clusterin γ chain 
(Upstate, Charlottesville, VA, USA), rabbit polyclonal anti-
XIAP (Cell Signaling Technology, Beverly MA, USA) and 
mouse monoclonal anti-β-tubulin (Sigma). Cells washed 
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with PBS were resuspended in RIPA buffer (10 mM Tris-
HCl pH7.4, 1% NP-40, 0.1% sodium deoxycholate, 
0.1 SDS, 150 mM NaCl, 1 mM EDTA) containing the 
protease inhibitor cocktail (Sigma, USA), and stored 
on ice for 30 min. After centrifugation at 13,000 rpm for 
30 min at 4 ˚C, the resultant supernatant was used as 
protein sample. Each protein content was measured 
with a DC protein assay kit (BIORAD, USA). 30 µg of 
each protein sample was subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to PVDF membrane. The membrane was 
blocked with 5% non-fat dry milk in 0.1 M Tris buffered 
saline containing 0.1% Tween-20 for 30 min, and incu-
bated overnight with primary antibodies at 4 ˚ C. The im-
munocomplex was detected with horseradish peroxidase 
conjugated anti-mouse or anti-rabbit IgG (Amersham 
Biosciences, USA) using an ECL system (Amersham 
Biosciences).
Semi-quantitative RT-PCR. Total RNA was isola-
ted from LNCaP cells and PC-3 cells using a Quick Prep 
Total RNA Extraction Kit (Amersham Biosciences) ac-
cording to manufacturer’s instruction. 2 µg of total RNA 
of each sample were reverse transcribed by using Super 
Script II RNase H-reverse transcriptase and oligo(dT) 
primer (Invitrogen). Primers and reaction conditions for 
each gene are summarized in Table 1. The housekeep-
ing transcript, elongation factor-1α (EF-1α), was used 
as a control for standardization [20]. Each PCR product 
was separated by electrophoresis on 2 % (w/v) agarose 
gel, and then visualized by ethidium bromide staining. 
To measure the density of each band, we use computer-
imaging analysis (BIO-1D Vilber Lourmat, France).
results 
CPT sensitivity in LNCaP and PC-3 cells. We exami-
ned CPT sensitivity in LNCaP cells and PC-3 cells using 
Hoechst 33,342 and PI double staining (Fig. 1). At 0.5 
µM of CPT, nuclear fragmentation and PI positive staining 
were observed in LNCaP cells, but not in PC-3 cells. When 
LNCaP cells were treated with 0.5 µM and 3.0 µM of CPT 
for 24 h, PI positive cells (necrotic or late apoptotic) and 
PI negative cells with nuclear fragmentation (apoptotic) 
were observed. At 0.5 µM CPT, less than 10% of cell death 
was mainly due to necrosis/late apoptosis, whereas at 
3.0 µM cell death was enhanced up to over 20% of total 
cells (~70% necrotic/late apoptotic and ~30% apoptotic) 
(Fig. 1, B). In contrast, in PC-3 cells the effect of CPT treat-
ment on cell death was much less pronounced.
Expression of clusterin, XIAP and survivin in 
prostate cancer cells. To investigate the mechanism 
underlying the different susceptibility of LNCaP cells and 
PC-3 cells to CPT, we examined expression levels of the 
Table. PCR Primers and Conditions
Gene 5’ primer 3’ primer Annealing Temperature (°C) Cycle
Clusterin AATACAACGAGCTGCTAAAGTCCT AATTTAGGGTTCTTCCTGGAGACT 62 25
Survivin AGAGGAACATAAAAAGCATTCGTC ACAGGAGCACAGTTGAAACATCTA 62 27
XIAP GCAGATCTAGTGAATGCTCAGAAA TACTTGGTAGCAAATGCTAATGGA 62 29
EF-1α CTCAGGTGATTATCCTGAACCATC AACAGTTCTGAGACCGTTCTTCCA 60 22
fig. 1. CPT-induced cell death in prostate cancer cell lines. (a) Morphological examination of CPT-induced cell death in LNCaP and 
PC-3 cells. Cell death was examined by the Hoechst 33342 and PI double staining. After 24 h incubation with 0.5 µM and 3.0 µM 
CPT, cells were stained and examined by fluorescence microscopy. (b) Time course of cell death in LNCaP and PC-3 cells. Both 
cells were exposed to 0.5 µM and 3.0 µM CPT for different time intervals (6, 24 h). After Hoechst 33,342 and PI double staining, 
over 500 cells were analyzed in each experiment
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proteins that exert the anti-apoptotic action by Western 
blotting. α-clusterin with 60 kDa has been known as anti-
apoptotic protein in normal state [21]. Its expression in 
LNCaP cells was marginal while it is much higher in PC-3 
cells (Fig. 2, a). The XIAP expression level was slightly 
higher in LNCaP cells compared to PC-3 cells (Fig. 2, b). 
As for survivin, there was no significant difference in both 
cell lines.
Changes in expression levels of clusterin, XIAP 
and surviving by CPT treatment. We examined CPT-
induced changes of clusterin and its mRNA by Western 
blotting and semi-quantitative RT-PCR. Interestingly, 
fig. 2. Clusterin and IAPs expression levels in LNCaP and PC-3 cells analyzed by Western blotting with polyclonal antibodies to 
human clusterin (a), XIAP (b) and survivin (c). Values represent means ± SD (bars) from three independent experiments. The blots 
are representative of three separate experiments
fig. 3. Expression of clusterin in LNCaP and PC-3 cells upon CPT treatment. (a) Time course of the protein expression of clusterin 
analysed by Western blotting with the specific antibody for human clusterin. Fold changes were determined from relative intensity 
compared to the control. Values represent means ± SD (bars) from three independent experiments. The blots represent one of three 
separate experiments with similar results. (b) Time course of expression of clusterin mRNA. Fold changes were determined from 
relative intensity to the control. Values represent means ± SD (bars) from three independent experiments
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clusterin protein expression appeared to increase by CPT 
treatment at 0.5 µM and 3.0 µM in PC-3 cells in a time-
dependent manner (Fig. 3, a). The temporal profile of its 
mRNA expression was reflected in the protein expression 
pattern (Fig. 3, b). However, clusterin expression in LN-
CaP cells did not change upon CPT treatment.
CPT-induced changes were also examined for pro-
tein and mRNA of XIAP. After treatment with 0.5 µM and 
3.0 µM CPT, the content of XIAP protein were shown to 
be decreased in both cell lines in  a time-dependent 
manner. The general patterns of the XIAP protein 
changes in LNCaP and PC-3 cells were compatible 
with those of mRNA changes (Fig. 4).
Further, we have examined survivin expression levels in 
LNCaP cells and PC-3 cells exposed to 0.5 µM and 3.0 µM 
CPT. CPT treatment resulted in reduced protein expression 
level in both cell lines. It’s interesting to note that in LNCaP 
cells there was a marked decrease in protein expression 
level of survivin upon 24 h-incubation with 0.5 µM CPT, 
while the treatment with 3.0 µM CPT caused only a small 
decrease (Fig. 5). The profile of expression levels was 
similar for proteins and respective mRNAs. In PC-3 cells, 
there was a trend to decreased survivin expression during 
treatment with either 0.5 µM or 3.0 µM CPT. 
As it is shown here, the expression levels were dis-
cordant between proteins and mRNAs, suggesting the 
transcriptional and/or post-transcriptional regulation 
of protein expression.
discussion
Prostate cancer is the most common in men and 
the major leading cause of cancer-related death in 
males. Prostate cancer is characterized by the andro-
gen-dependent growth at the early stage and can be 
effectively treated by hormone ablation [1]. However, 
prostate cancer cells often become androgen-inde-
pendent and refractory to chemotherapy. Despite 
abundant investigations, the molecular mechanism 
underlying the resistance to chemotherapy-induced 
apoptosis remains poorly understood. For in vitro 
studies, androgen-sensitive LNCaP and androgen-
resistant PC-3 cell lines have been most commonly 
used as a model system to search for biochemical or 
molecular differences between these two cell lines [1, 
22]. Wang et al. [18] have demonstrated that LNCaP 
cells produced ceramide, a key apoptotic mediator, 
by CPT treatment while PC-3 cells were defective 
in the ceramide generation, and concluded that the 
fig. 4. Expression of XIAP in LNCaP and PC-3 cells upon CPT-treatment. (a) Time course of the protein expression of XIAP analyzed 
by Western blotting with the specific antibody for human XIAP. Fold changes were determined from relative intensity to the control. 
Values represent means ± SD (bars) from three independent experiments. The blots represent one of three separate experiments 
with similar results. (b) Time course of expression of XIAP mRNA analized by RT-PCR. Fold changes were determined from relative 
intensity to the control. Values represent means ± SD (bars) from three independent experiments
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loss of ceramide formation was responsible for the 
anti-apoptotic response of PC-3 cells. Our study 
using ceramide synthetase inhibitor suggested that 
ceramide generated via its de novo synthesis may not 
play a primary role in CPT-induced apoptotic cell death 
in LNCaP cells [19]. Recently, studies by Pchejetski et 
al. and our report [23, 24] have shown that expression 
and activity of oncogenic sphingosine kinase 1 were 
higher in PC-3 cells than in LNCaP cells and that the 
enzyme expression level was enhanced by CPT-treat-
ment in PC-3 cells. On the other hand, we have previ-
ously performed the comparative proteomic analysis 
to examine differential protein expression in PC-3 
and LNCaP cells [25]. Several proteins preferentially 
expressed in PC-3 cells were identified; they include 
annexin A1, glutathione-S-transferase (GST) pi and 
glucose-regulated protein (GRP) 78/Bip which are 
thought to be involved in the anti-apoptotic response. 
However, because of the low level expression, we were 
unable to detect other anti-apoptotic proteins includ-
ing clusterin and inhibitor of apoptosis proteins (IAPs) 
known as endogenous caspase inhibitors. Therefore, 
in the current study, we have examined and compared 
the expression profiles of clusterin, XIAP and survivin, 
and their changes by CPT-treatment by Western blot-
ting and RT-PCR analysis.
Clusterin, also known as apolipoprotein J or tes-
tosterone-repressed prostate message 2 (TRPM-2), 
is a cytosolic glycoprotein that has multiple functions 
including regulation of apoptosis [21]. There is accu-
mulating evidence suggesting that clusterin is an anti-
apoptotic protein associated with chemoresistance. 
In fact, recent study has shown that clusterin-over-
expressing cells are highly resistant to CPT- and eto-
poside-mediated apoptosis [26]. We have observed 
a striking difference in clusterin protein expression 
between LNCaP and PC-3 cells, as shown in Fig. 2, a; 
abundant in PC-3 cells and marginal in LNCaP cells. 
This predominant expression of clusterin may at least 
in part account for resistance to CPT in PC-3 cells but 
not in LNCaP cells. Moreover, it is of great interest 
to note that the expression of clusterin protein was 
enhanced in a time-dependent fashion within 24 h 
following CPT-treatment in PC-3 cells. This enhanced 
clusterin expression was considered to be regulated 
at the transcriptional regulation.
The IAP proteins XIAP and survivin expression were 
shown to be at the nearly same level, which is distinct 
fig. 5. Expression of survivin in LNCaP and PC-3 cells upon CPT-treatment. (a) Time course of the protein expression of surviving 
analyzed by Western blotting with the specific antibody for human survivin. Fold changes were determined from relative intensity to 
the control. Values represent means ± SD (bars) from three independent experiments. The blots represent one of three separate 
experiments with similar results. (b) Time course of survivin mRNA expression analyzed by RT-PCR. Fold changes were determined 
from relative intensity to the control. Values represent means ± SD (bars) from three independent experiments
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from clusterin. Furthermore, in sharp contrast to clus-
terin, CPT-induced up-regulation of XIAP and survivin 
was not observed in PC-3 cells as well as LNCaP cells. 
Instead, the content of both anti-apoptotic proteins 
was reduced in a time-dependent fashion in both cell 
lines. The down-regulated expression of these proteins 
is favoring for induction of the apoptotic process. Un-
expectedly, the survivin level was markedly reduced 
in LNCaP cells exposed to 0.5 µM CPT compared to 
3.0 µM CPT-treated cells, and this profound decrease 
in the protein level was well correlated with mRNA 
expression (Fig. 5). At present, we have no adequate 
explanation for this finding and further experiments 
are needed to address this phenomenon.
Taken together, the comparative investigations of 
the expression profiles for three anti-apoptotic pro-
teins provide at least in part some evidence suggesting 
that clusterin may take a greater part in resistance to 
CPT in PC-3 cells, compared to XIAP and survivin.
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Экспрессия кластерина, xiap и сурвивина в клетках 
рака предстательной железы, устойчивых и 
резистентных к камптотецину
Цель: известно, что кластерин и белки-ингибиторы апоптоза семейства IAP, такие как сурвивин и XIAP, связаны 
с химиорезистентностью опухолевых клеток. Задача исследования — определить уровни экспрессии указанных белков 
в линиях опухолевых клеток предстательной железы, чувствительных (LNCaP) и устойчивых (PC-3) к действию 
камптотецина (CPT) — ингибитора топоизомеразы I. Методы: клетки LNCaP и PC-3 инкубировали с CPT, после чего 
анализировали количество погибших клеток с использованием двойного окрашивания реактивом Херста 33 342 и пропидиум-
иодидом. Экспрессию кластерина, XIAP и сурвивина на уровне белка и мРНК оценивали методами Вестерн-блоттинга и 
полуколичественного РТ-ПЦР соответственно. Результаты: установлено, что вследствие 24-часовой инкубации клеток с 
0,5 и 3,0 µM CPT определяют более значительный процент гибели клеток линии LNCaP, чем таковых PC-3. Данные Вестерн 
блот анализа выявили, что в клетках линии PC-3 количество кластерина в 5 раз больше, а XIAP — меньше, чем в клетках 
линии LNCaP, в то время как экспрессия сурвивина одинакова в обеих клеточных линиях. Инкубация клеток с 0,5 и 3,0 µM 
CPT приводила к снижению уровня сурвивина и XIAP в обеих линиях. Экспрессия кластерина на уровне мРНК и белка не 
изменялась при действии CPT на клетки линии LNCaP, однако повышалась в клетках линии PC-3. Выводы: полученные 
данные свидетельствуют о том, что в развитии резистентности к камптотецину клеток линии PC-3 кластерин может играть 
более важную роль, чем сурвивин и XIAP.
Ключевые слова: LNCaP, PC-3, кластерин, XIAP, сурвивин, камптотецин.
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